A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma (Q37399436)

20 August 2017

A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma (English)

1 reference

20 August 2017

1 reference

Abby B Siegel

1

1 reference

20 August 2017

Rupa Narayan

2

1 reference

20 August 2017

Rosa Rodriguez

3

1 reference

20 August 2017

Abhishek Goyal

4

1 reference

20 August 2017

Judith S Jacobson

5

1 reference

20 August 2017

Kara Kelly

6

1 reference

20 August 2017

Elena Ladas

7

1 reference

20 August 2017

Paul J Lunghofer

8

1 reference

20 August 2017

Ryan J Hansen

9

1 reference

20 August 2017

Daniel L Gustafson

10

1 reference

20 August 2017

Thomas W Flaig

11

1 reference

20 August 2017

Wei Yann Tsai

12

1 reference

20 August 2017

David P H Wu

13

1 reference

20 August 2017

Valerie Lee

14

1 reference

20 August 2017

Heather Greenlee

15

1 reference

20 August 2017

11 June 2013

1 reference

Integrative Cancer Therapies

20 August 2017

1 reference

20 August 2017

13

1 reference

20 August 2017

1

1 reference

20 August 2017

46-53

1 reference

Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3866213

6 September 2017

Cancer statistics, 2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3866213

Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3866213

Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3866213

Sorafenib: where do we go from here?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3866213

A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL)

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3866213

Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3866213

Sorafenib in advanced hepatocellular carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3866213

Design and endpoints of clinical trials in hepatocellular carcinoma.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3866213

In silico and in vitro pharmacogenetic analysis in mice

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3866213

Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3866213

Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3866213

The safety and efficacy of a silymarin and selenium combination in men after radical prostatectomy - a six month placebo-controlled double-blind clinical trial.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3866213

First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3866213

A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3866213

A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3866213

Screening for hepatocellular carcinoma: The rationale for the American Association for the Study of Liver Diseases recommendations

2 October 2018

1 reference

Crossref

https://api.crossref.org/works/10.1177%2F1534735413490798

Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23757319

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23757319

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1177/1534735413490798

1 reference

20 August 2017

1 reference

20 August 2017

1 reference